Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Benedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen, Mats Holmberg, Morten Sørensen, Michael Kosteljanetz, Helle Broholm, Marie-Thérése Stockhausen, Hans Skovgaard Poulsen
Dyk ned i forskningsemnerne om 'Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial'. Sammen danner de et unikt fingeraftryk.